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Background: Observational investigations into the health impacts of low-calorie sweeteners 2 
(LCS) in humans fail to adequately identify or fully characterize LCS consumption. 3 
Objectives: We aimed to utilize a novel biomarker approach to investigate exposure to 5 LCS 4 
and to test whether reported LCS beverage (LCSB) consumption effectively identifies exposure 5 
to LCS in adults. 6 
Methods: In this cross-sectional analysis, two population studies were conducted in adults. 7 
Urinary excretions of 5 LCS, namely acesulfame-K, saccharin, cyclamate, sucralose and steviol 8 
glycosides, were simultaneously determined using liquid chromatography tandem-mass 9 
spectrometry. In Study 1, previously collected 24-hr urine samples (n = 357) were analyzed. In 10 
Study 2, previously collected 24-hr urine samples (n = 79) were analyzed to compare urinary 11 
excretions of LCS with self-reported LCSB consumption for identifying LCS exposure. 12 
Exposure to LCS was characterized using descriptive statistics and Chi-square tests were 13 
performed to assess associations between age-groups and LCS excretion, and to assess the 14 
proportion of individuals identified as LCS consumers using biomarker data or reported LCSB 15 
consumption. 16 
Results: A total of 341 adults (45% males) and 79 adults (39% males) were included in the final 17 
analysis of Studies 1 and 2 respectively. In Study 1, over 96% of samples contained at least one 18 
LCS and almost 60% contained three or more LCS. A greater proportion of younger adults (< 40 19 
y) excreted three or more LCS than older adults (> 40 y) (p < 0.001). In Study 2, a much higher 20 
prevalence of LCS consumption was observed using biomarker data (92%) compared to reported 21 
LCSB consumption (6%) (p < 0.001). 22 
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Conclusions: This work indicates widespread exposure to LCS suggesting that population-based 23 
research to date into LCS exposure and health may be flawed. Therefore, a urinary biomarker 24 
approach offers considerable potential for more robust investigations in this area. 25 
Keywords: low-calorie sweeteners; non-nutritive sweeteners; biomarkers; acesulfame-K, 26 




Consumption of LCS, which provide a sweet taste with little or no energy, is becoming more 29 
widespread across all age-groups in the Unites States (1). Indeed, this is likely to increase further 30 
with ongoing international efforts to limit free sugar consumption to 5% (2) or 10% (3) of total 31 
energy intake. Although the safety of LCS is established prior to regulatory approval, and current 32 
intakes are generally within acceptable limits (4), debate continues around LCS and health. To 33 
date, experimental research has tended to yield favorable results whilst observational research 34 
has produced a more mixed picture (5). 35 
Most cohort studies investigating LCS in the context of health use low-calorie sweetened 36 
beverages (LCSB) intake as a surrogate marker of overall LCS exposure. Such an approach is 37 
unlikely to adequately capture LCS exposure given that LCSB are only one of many sources of 38 
LCS. Furthermore, LCS may be used at different concentrations within various LCSB and they 39 
are often used in combinations within the same product. Therefore, inadequate exposure 40 
assessments may be an important contributor to the observed variation in observational data, as 41 
has been highlighted elsewhere (6, 7). Most cohort studies also fail to discern intakes of specific 42 
LCS despite the different biological fates of the various LCS following ingestion (8) and the 43 
potential differential effects within the body (9). As such, alternative approaches, whereby LCS 44 
consumption is reliably identified and more effectively characterized, will significantly enhance 45 
investigations of the potential health impacts of LCS use.   46 
Biomarker approaches for assessing dietary intakes provide an opportunity to obtain objective 47 
intake data (10), thereby facilitating more reliable investigation of diet and health. Five 48 
commonly used LCS, namely acesulfame-K, saccharin, cyclamate, sucralose and steviol 49 
glycosides, are excreted to varying degrees via the urine following ingestion and a novel liquid 50 
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chromatography tandem-mass spectrometry (LC-ESI MS/MS) method of simultaneously 51 
determining urinary excretions of these LCS has been developed and validated (11).  52 
Using this novel methodology, the present work aimed to assess exposure to these five LCS in a 53 
free-living adult population and to compare biomarker data with a commonly used surrogate for 54 
LCS intake (namely LCSB intake). The main outcome measures were prevalence of exposure, 55 
identification of specific LCS being excreted and total excretion of these LCS. It was 56 
hypothesized that actual prevalence of exposure to LCS (from urinary biomarker data) would be 57 
higher than that reported elsewhere in published exposure assessments as well as observed using 58 
LCSB intake data.  59 
METHODS AND PARTICIPANTS 60 
Two separate cross-sectional studies were conducted in adults to address the research questions. 61 
To assess LCS intake in a free-living adult population, urine samples previously collected as part 62 
of a salt and iodine excretion study in the Netherlands in 2010 (12) were analyzed. To compare 63 
biomarker data with self-reported intakes of LCSB for identifying LCS consumption, 24-hr urine 64 
samples previously collected as part of a European hydration study (13) were analyzed. 65 
Assessment of LCS exposure in a free-living adult population (Study 1) 66 
24-hr urine samples (n = 357) were collected from free-living adults (aged 19-70 y) as part of a 67 
study investigating intakes of salt and iodine (12). In brief, participants collected a single 24-hr 68 
urine sample after receiving comprehensive written and verbal instructions: the first void of the 69 
morning was discarded and all urine for the subsequent 24-hr period up to and including the first 70 
sample of the following day was collected. The completeness of the sample was verified by total 71 
creatinine excretion along with verbal confirmation from participants. Renal impairment and 72 
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pregnancy were exclusion criteria for the study. Data on general lifestyle factors including level 73 
of education and smoking status were also available and used in this analysis. The study was 74 
approved by the Medical Ethics Committee of the University Medical Centre Utrecht. 75 
Comparison of LCSB intake with LCS biomarker data for identifying LCS consumers 76 
(Study 2) 77 
To compare urinary biomarker data with self-reported LCSB intake data for identifying LCS 78 
consumers, a study was conducted to analyze a randomly selected sub-sample of 24-hr urine 79 
samples (n = 79) that were previously collected as part of a multi-center European hydration 80 
study for which detailed information on the study protocol is reported elsewhere (13). In brief, 81 
participants collected urine samples over 7 consecutive 24-hr periods while maintaining a 7-day 82 
food diary in which all foods and beverages consumed during that period were recorded. The 83 
completeness of the 24-hr collections were determined by total creatinine excretion. For the 84 
present work, a single 24-hr urine sample, along with reported intake of LCSB related to the day 85 
of urine sampling, were considered for analysis. Participants were categorized as consumers or 86 
non-consumers of LCS based on reported consumption of LCSB on the day of the urine 87 
collection. However, intakes of specific LCS were not determined using reported LCSB 88 
consumption as concentration data for LCS are not available from dietary analysis software 89 
packages or food composition databases. The study was approved by the Agricultural University 90 
of Athens Research Ethics Committee (Study No. 197/27-02-2012). 91 
Urine sample analysis 92 
All urine samples were stored at -80 0C until analysis. Samples were analyzed in duplicate using 93 
a novel LC-ESI MS/MS methodology to simultaneously determine urinary concentrations of 94 
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acesulfame-k, saccharin, cyclamate, sucralose and the excretory metabolite of steviol glycosides, 95 
steviol glucuronide as detailed elsewhere (11). Intra-batch and inter-batch % coefficients of 96 
variation were below 10% for all compounds of interest. 97 
Prevalence of exposure to LCS and estimated intakes using urinary excretions 98 
An individual was identified as a consumer of LCS if urinary excretions were detected. Total 24-99 
hr urinary excretions of the LCS were used in conjunction with published pharmacokinetic data 100 
(14-22) to estimate recent intake of the respective LCS. 101 
To allow comparisons between intakes and acceptable daily intakes (ADI), it is necessary to 102 
express intakes in relation to body weight i.e. mg/kg body weight. However, information on 103 
body weight was not collected as part of the salt and iodine excretion study (12). Therefore, data 104 
from the nationally representative Dutch National Food Consumption Survey (DNFCS) 2007-105 
2010 (23), which reported sex and age-group specific mean self-reported body weight, were used 106 
to provide an estimate of exposure within this population. Uncertainties exist when applying 107 
such assumptions in relation to body weight; however, it was nevertheless deemed worthwhile to 108 
express estimated intake data in this way to aid interpretation of the results. The ADI for steviol 109 
glycosides is expressed as steviol equivalents; therefore, steviol glucuronide values were 110 
converted to steviol equivalents applying a factor of 0.643 (calculated based on the ratio of the 111 
respective molecular weights, namely 317/493) to allow for comparison.  112 
Using these data, exposure was estimated and expressed as % of the ADI using the following 113 
equation: 114 
[(Total excretion ÷ % absorption)/ (Body weight (kg))] ÷ ADI × 100 115 
Statistical analysis 116 
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Statistical analysis was conducted using the Statistical Package for the Social Sciences (SPSS) 117 
(Version 25.0, Chersey, UK). The distribution of continuous variables was assessed using the 118 
Shapiro-Wilk test; for data that were not normally distributed, non-parametric tests were utilized. 119 
For both Study 1 and Study 2, descriptive statistics were used to assess the general characteristics 120 
of the study populations. In Study 1, Chi-square test was used to assess level of education in 121 
males and females whilst mean differences in age, urine volume and creatinine excretion 122 
between males and females were assessed using independent samples t-test. The main outcome 123 
measures related to LCS exposure were prevalence of LCS excretion, the number of LCS 124 
excreted, as well as identification of specific LCS in the urine. Associations between the number 125 
of LCS detected and age, sex and level of education were assessed using Chi-square test. To 126 
assess the relationship between age and exposure to multiple LCS, the cohort was collapsed into 127 
three age-groups, defined as: 18-39 y (n = 119), 40-55 y (n = 100) and ≥ 56 y (n = 122). Further 128 
analyses were conducted to investigate relationships between sex and age in terms of absolute 129 
LCS excretions. LCS excretions and estimated intakes in males and females were compared 130 
using Mann Whitney U test. The relationship between age and absolute excretions of each LCS 131 
was explored using simple linear regression analysis. In Study 2, Chi-square test was used to 132 
assess whether the proportion of those identified as LCS consumers differed between the 133 
biomarker data and the surrogate measure i.e. reported LCSB intake.  A P value of <0.05 was 134 
considered as statistically significant throughout. 135 
RESULTS 136 
Assessment of LCS exposure in a free-living adult population (Study 1) 137 
A total of 357 participants submitted a urine collection in the salt and iodine excretion study. 138 
From these, 16 participants were excluded prior to statistical analysis owing to an unknown urine 139 
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sample volume (n = 1) or incomplete or incorrect urine collections (n = 15) resulting in a study 140 
population of n = 341 (154 males, 187 females) (see Supplemental Fig. 1). The general 141 
characteristics of the study participants are presented in Table 1. Males and females did not 142 
differ in terms of age, level of education or mean volume of urine samples; however, as 143 
expected, males excreted more creatinine than females (P < 0.0001) (Table 1). 144 
A total of 96% of urine samples (n = 328) contained at least one LCS. The number of LCS 145 
detected was not associated with sex (P = 0.87) or level of education (P = 0.51). 146 
The prevalence of exposure to multiple LCS was high with approximately 60% of urine samples 147 
containing three or more LCS. A significant association between age-groups and exposure to 148 
multiple LCS was observed with a higher proportion (74%) of those aged 39 y or younger 149 
excreting 3 or more LCS than those aged 40-55 y (60%) or 56 y and older (46%) (P < 0.001). 150 
When stratified by sex, a higher proportion of younger males (76%) exposed to multiple LCS as 151 
compared to their older counterparts (40-55 y, 63%; 56 y and older, 36%) (P < 0.0001). No 152 
significant trend was observed for females (39 y and younger, 70%; 40-55 y, 56%; 56 y and 153 
older, 55%) (P = 0.14). 154 
Absolute urinary excretions ranged from 0-200 mg/d for acesulfame-K, 0-51 mg/d for saccharin, 155 
0-141 mg/d for cyclamate, 0-2 mg/d for sucralose and 0-15 mg/d for steviol glucuronide, 156 
equating to 0-10 mg/d in steviol equivalents (for median, IQR and 95th percentile data, see Table 157 
2). No differences were observed in total excretion of acesulfame-K, saccharin, cyclamate, 158 
sucralose or steviol between male and female consumers (Table 2). Indeed, age, level of 159 
education and sex were not associated with total excretion of acesulfame-K, saccharin, cyclamate 160 
and steviol glucuronide; however, age was a significant, albeit weak, predictor of sucralose 161 
excretion (r2 = 0.07, P = 0.037).  162 
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Estimated intakes of the LCS were within the stated limits with respect to the European Union 163 
ADI (as summarized in Table 3). No significant differences were observed in estimated intakes 164 
in relation to ADI between males and females for acesulfame-K, saccharin, sucralose and steviol; 165 
however, for cyclamate, females consumed a higher % of the ADI than males (P = 0.017). 166 
Comparison of LCSB intake with LCS biomarker data for identifying LCS consumers 167 
(Study 2) 168 
In Study 2, 79 participants (31 males, 48 females) with a mean age of 36.7 ± 13.7 y were 169 
included in the analysis. BMI of the sample was 24.5 ± 4.0 kg/m2 and the mean volume of the 24-170 
hr urine sample was 1363 ± 549 mL/d. A total of 6% (n = 5) reported consumption of LCSB on 171 
the day of the urine collection. However, a significantly greater proportion of individuals (92%, 172 
n = 73) were identified as LCS consumers when urinary biomarker data were considered (P < 173 
0.001) (Figure 1). The most commonly detected LCS were saccharin (82%, n = 65), acesulfame-174 
k (51%, n = 40) and cyclamates (34%, n = 27). In relation to sucralose and steviol glycosides, 175 
30% (n = 24) and 11% (n = 9) of participants excreted these LCS respectively. Again, prevalence 176 
of exposure to multiple LCS was high with 62% of participants excreting two or more LCS and 177 
42% excreting three or more LCS. To account for the potential contribution of non-dietary 178 
sources of saccharin, non-saccharin urinary excretion was also considered; when saccharin 179 
excretion was excluded 63% (n = 50) were still identified as LCS consumers, a percentage which 180 
was still significantly more than that identified via the self-reported data (P < 0.001). 181 
DISCUSSION 182 
Building upon existing evidence (7), the present work has utilized a novel biomarker approach to 183 
demonstrate for the first time that exposure to LCS is much more widespread than previously 184 
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reported. Such findings, which support the use of alternative methodologies for exposure 185 
assessments, and promote more robust measurement of LCS exposure, will have potentially 186 
important implications for research in this area. A further significant and novel finding, 187 
considering recently published work that suggests differential effects of specific LCS in relation 188 
to body weight (9), is that exposure to multiple LCS is also highly prevalent. 189 
Study 1 was conducted to investigate how widespread actual exposure to LCS might be based on 190 
urinary excretions compared to published exposure data, which relies on self-reported dietary 191 
intake data. Furthermore, by analyzing urinary excretions, exposure to the specific LCS of 192 
interest can be established. Study 1 found that, within a Dutch adult population, 96% of urine 193 
samples contained at least one LCS, which is well in excess of the 59% of the Dutch population 194 
aged 7 y and older reported to be consuming "artificially sweetened" products in the DNFCS at 195 
that time (23). This may be partly explained by the detection of saccharin, which is commonly 196 
used in oral hygiene products in Europe, in approximately 90% of urine samples. Interestingly, 197 
most formal exposure assessments of LCS do not consider non-dietary sources of LCS such as 198 
oral hygiene products, e-cigarette products and supplements (24-30), potentially resulting in 199 
underestimation of exposure within the population. This may have significant implications for 200 
research in the area of LCS and health given that the potential differential effects of individual 201 
LCS has increasingly gained attention in recent times (9, 31). Indeed, a recent RCT found that a 202 
saccharin-sweetened beverage, unlike other LCSB, had similar effects as a sucrose-sweetened 203 
beverage on body weight and therefore research that discerns intakes of individual LCS seems 204 
warranted (9).  Of the other LCS investigated, acesulfame-K and cyclamate were the most 205 
commonly detected, found in 74% and 68% of samples respectively, which was still higher than 206 
that reported in the DNFCS (23). A lower prevalence of exposure has been reported elsewhere, 207 
13 
 
even in younger populations, which are often considered to have potentially high intakes (25, 28, 208 
29). Previous research suggests that individuals aged 45 y or older are more likely to use LCS 209 
(32); however, our work suggests that younger adults (39 y and younger) excreted a higher 210 
number of LCS, albeit in similar quantities to those aged over 39 y. Further work should 211 
investigate this finding in nationally representative sample. Intakes of LCS in US children and 212 
adults were recently assessed using data from the National Health and Nutrition Examination 213 
Survey and it was found that the prevalence of LCS consumption increased from 6.1 to 12.5% 214 
for children and 18.7 to 24.1% for adults (1). Although this prevalence is much lower than the 215 
findings of the present study, it suggests an upward trend in LCS use, which is not surprising 216 
given the increasingly widespread application of LCS and global efforts to reduce free sugar 217 
consumption. It is feasible that, given the ubiquity of LCS in today's market, even though the use 218 
of LCS in products must be clearly labelled (33), inadvertent consumption of LCS may be 219 
occurring. The French Agency for Food, Environmental and Occupational Health and Safety 220 
(ANSES) (34) suggested the use of better designed questionnaires in future cohort studies so that 221 
intakes of LCS, individually and in combinations, could be better understood; a urinary 222 
biomarker approach potentially addresses this important research need.  223 
Whilst the current work reliably indicates that exposure to LCS is more widespread than 224 
previously reported, it was important to also attempt to quantitate intakes using the excretion 225 
data to aid further interpretation. Owing to the lack of body weight data in Study 1, assumptions 226 
were made based on published age- and gender-specific mean body weight for a Dutch 227 
population from this time (23). Published pharmacokinetic data (14-22) were then used to 228 
generate estimated intakes and compare it to assigned ADIs. Given that the application of a 229 
biomarker approach to assess LCS intake is relatively novel, there is currently an acknowledged 230 
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inherent uncertainty in using such an approach to estimate intake. However, this approach makes 231 
it possible to provide estimated data on intakes that is more informative than the current reliance 232 
on surrogate measures of LCS intake such as self-reported LCSB consumption. Estimated 233 
intakes in the present work are within the respective European ADIs and agree with the findings 234 
of a recent comprehensive review of global intakes (4). Intake data relating to the Dutch 235 
population have been presented in a few studies (35, 36). Van Rooij-van den Bos et al. (35) 236 
reported average intakes of <0.5%, 1.0% and 0.4% of the ADI for acesulfame-K, cyclamate and 237 
saccharin respectively and our estimates yielded similar results (0.7%, 0.6% and 0.2% of the 238 
ADI). Hendriksen et al. (36) implemented a “worst-case” scenario to generate estimates for 239 
young males and females who participated in the DNFCS 2007-2010 with high intakes (defined 240 
as 95th percentile) in relation to the ADI being 29% and 27% for acesulfame-K, 37% and 29% 241 
for cyclamate and 4% and 3% ADI for saccharin respectively. The present study estimated that 242 
high intakes (also defined as 95th percentile) were much lower for acesulfame-k (males, 9%; 243 
females 11%) and similar for cyclamates (males, 16%; females 27%) and saccharin (males, 5%; 244 
females, 7%). It should be noted that LCS exposure studies often focus on groups expected to 245 
have high intakes such as children/teenagers (25, 27, 29, 30) or those living with diabetes 246 
mellitus (26, 28), and therefore, utilizing a urinary biomarker approach to investigate these 247 
populations may yield different results. In 2010 sucralose was a relatively new LCS on the EU 248 
market, having received a favorable opinion from the Scientific Committee on Food (SCF) in 249 
2000 (37), and it evidently was not as commonly consumed in this population as acesulfame-K, 250 
saccharin and cyclamate at this time. However, a study of LCS exposure in the Belgian 251 
population (38) covering approximately the same period as the present study calculated median 252 
exposure of 0.39 mg/kg body weight, equating to 3% of the ADI which is significantly higher 253 
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than our estimate of 0.5% of the ADI. An interesting finding, which would support integrating 254 
biomonitoring within formal exposure assessments to ensure comprehensive and accurate data, 255 
was that steviol glucuronide was detected in approximately 6% of the urine samples indicating 256 
exposure to steviol glycosides prior to its approval for use in the EU in 2011 (39, 40) (the urine 257 
samples from the present study were collected a year before EU approval of steviol glycosides). 258 
Our data indicate that median intake in consumers equated to 0.2% of the ADI, which was 259 
similar to that reported by Chung et al., (41) in a Korean population and lower than the more 260 
recent study conducted by Ha et al. (42) who reported a mean intake of 6.5%. 261 
Study 2, which compared self-reported intake data on LCSB and biomarker data, also suggests 262 
higher prevalence of exposure within the free-living population than previously reported. 263 
Importantly, it suggests that using LCSB as a surrogate for overall LCS intake may not 264 
effectively identify LCS consumers and therefore, alternative, more comprehensive methods of 265 
investigating intakes are required for population-based studies to assess the health impacts of 266 
LCS use more effectively. Furthermore, the present study demonstrates that exposure to multiple 267 
LCS is common and, given the chemical diversity of LCS, obtaining qualitative data in relation 268 
to exposure to specific LCS is essential for the reliable assessment of the benefits and risks of 269 
LCS. 270 
The strengths and limitations of the present work should be discussed. A significant strength of 271 
the current work is that a highly specific and sensitive methodology has been utilized to identify 272 
and characterize exposure to LCS by determining urinary excretions of the respective LCS. 273 
Whilst the excretion metabolites of these LCS are highly specific to the respective LCS, as 274 
previously alluded to, further work is needed to fully characterize the relationship between 275 
ingestion and urinary excretion, thereby facilitating extended validation of this biomarker 276 
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approach. Parameters of interest include the investigation of variation between individuals as 277 
well as within individuals under different consumption conditions and in specific population 278 
groups of interest; for example, children or individuals living with obesity or diabetes. Utilizing 279 
such a biomarker approach can overcome several important limitations of self-reported intake 280 
data by generating objective measures of intake; however, a recognized limitation of this 281 
approach is that it cannot identify exposure to all approved LCS or the source of LCS within the 282 
diet. Aspartame, which is a commonly used LCS in the US, is metabolized to its constituent 283 
parts, phenylalanine, aspartic acid and methanol following ingestion (8). Given that all three 284 
constituents of aspartame are commonly found elsewhere in the diet, no specific biomarkers for 285 
determining exposure exist. Therefore, to gain a comprehensive picture of LCS exposure, a 286 
combination of a biomarker approach and self-reported intake data may yield the most useful 287 
data in future research. For Study 2, a relatively small sample was investigated, and LCSB intake 288 
data were specific only to the day of urine sample collection, thereby likely limiting the number 289 
of LCS consumers identified. Analysis of dietary intake data covering a longer duration may 290 
have identified more LCS consumers but is unlikely to have reversed the finding. The 291 
completeness of the 24-hr urine collections was assessed in both studies based on the total 292 
excretion of creatinine which may not be a reliable measure of compliance (43, 44); the gold 293 
standard being the use of para-aminobenzoic acid (45). It has been suggested that future research 294 
should attempt to discern the intakes of individual LCS so that the health impact of consumption, 295 
both individually and in combinations, can be investigated (34). A major strength of utilizing a 296 
biomarker approach, is that exposure to specific LCS can be assessed, which significantly 297 
improves the overall exposure assessment both quantitatively and qualitatively. If the findings of 298 
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Study 2 are replicated in larger populations, doubt must be cast on the findings of many cohort 299 
studies, which have generally used LCSB as a marker overall LCS consumption. 300 
To conclude, a urinary biomarker approach has demonstrated that exposure to LCS is much more 301 
widespread in adults than previously reported. It is essential that more reliable and 302 
comprehensive methods of assessing LCS intakes are developed and utilized so that the potential 303 
health impacts can be assessed more effectively. The biomarker approach presented in the 304 
current work overcomes several important limitations with current research approaches by 305 
generating objective and more comprehensive data on exposure to five commonly used LCS. 306 
Therefore, future research should incorporate enhanced methodologies such as this in order to 307 
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Table 1. General characteristics of adults who participated in the salt and iodine excretion study (Study 1)1 
 Overall 
n = 341 
Females 
n = 187 
Males 
n = 154 
P value3 
Age (y) 46 ±15 46 ±14 47 ±15   0.43 
     
Level of education2      0.10 
   Low   62 (18)   26 (14)   36 (23)    
   Medium 174 (51) 104 (56)   70 (46) 
   High   99 (29)   53 (28)   46 (30) 
   Other     6 (2)     4 (2)     2 (1) 
     
Urine volume (mL/d) 2002 ±787 1973 ±721 2036 ±862   0.47 
Creatinine (mmol/d)  12.0 ±4.0    9.8 ±2.2  14.7 ±4.0 <0.001 
1 Values are means ± SDs [for age, urine volume and creatinine] or n (%) [for level of education] 
2 Level of education defined as; Low, including primary school, lower vocational, low or intermediate general education; Medium, including intermediate 
vocational education and higher general education; High, including higher vocational education and university; Other, level of education not defined. 
3 Statistical analysis was carried out to investigate differences between males and females. Age, urine sample volume and creatinine excretion were assessed 




Table 2. Urinary excretion of five low-calorie sweeteners in a free-living adult cohort (n = 341)1 
 Number of consumers2 








Acesulfame-K  252 (74) 5 (0-21) [61] 6 (0-23) [65] 4 (0-19) [59] 0.60 
Saccharin  308 (90) 0 (0-4) [22] 1 (0-4) [23] 1 (0-4) [19] 0.64 
Cyclamate  232 (68) 1 (0-11) [53] 3 (0-11) [57] 4 (0-10) [38] 0.05 
Sucralose  67 (20) 0 (0-0) [1] 0 (0-0) [1] 0 (0-1) [2] 0.63 
Steviol  20 (6) 0 (0-1) [14] 0 (0-1) [-] 0 (0-3) [-] 0.90 
1 Values are median (IQR) [95th percentile] or n (%). IQR, inter-quartile range. '-', not determined owing to insufficient participant data (i.e. n < 5). 
2 Percentage of all participants who, based on the biomarker approach, had consumed the given LCS. 
3 Statistical analysis was carried out to investigate differences between males and females. Urinary excretions of the compounds of interest were assessed with Mann-













Overall Females Males 
(% ADI)3 (% ADI)3 (% ADI)3 
Acesulfame-K 0-9 90.0 0.73 (0.07-3.30) [9.14] 0.90 (0.08-3.83) [10.57] 0.47 (0.06-2.79) [8.77] 
Saccharin  0-5 88.0 0.17 (0.05-1.21) [6.43] 0.18 (0.06-1.33) [7.23] 0.17 (0.04-0.98) [4.95] 
Cyclamate  0-7 40.0 0.63 (0.02-5.07) [24.25] 1.34 (0.03-5.40) [27.11] 0.15 (0.01-4.29) [16.04] 
Sucralose  0-15 14.5 0.12 (0.04-0.23) [0.80] 0.12 (0.06-0.19) [0.75] 0.14 (0.03-0.33) [1.12] 
Steviol  0-4 60.0 0.08 (0.05-0.40) [4.45] 0.10 (0.05-0.44) [-] 0.07 (0.04-1.40) [-] 
1 Values are median (IQR) [95th percentile]. ADI, acceptable daily intake (expressed as mg/kg body weight per day); IQR, inter-quartile range; '-', not determined owing to 
insufficient participant data (i.e. n < 5). 
2 Average absorption based on published pharmacokinetic data (14 – 22).  




LEGENDS FOR FIGURES 
 
Figure 1. Comparison of self-reported LCSB consumption and biomarker data for identifying 
LCS consumption (n = 79). * Different from LCSB consumption, P < 0.001 as tested by Chi-
square test. LCS, low-calorie sweeteners; LCSB, low-calorie sweetened beverages. 
